Loading...

ZNTL ZENTALIS PHARMACEUTICALS INC Expansion Plans 8-K Filing

ZNTL

ZNTL

ZENTALIS PHARMACEUTICALS INC

(ZNTL)

2025 8-K

Show Summary

Summary

New Product Launches

Investor Meetings

Financial Statements

Investor Meetings

Financial Results

Investor Update

Azenosertib Development

Workforce Reduction

Board Appointment

Financial Results Announcement

Annual Meeting Voting Results

Appointment of Director

Financial Results

Departure of Directors or C...

Regulation FD Disclosure

Financial Results Announcement

Bylaws Amendments

Appointment of Chief Medica...

License Agreement with Immu...

Financial Results and Busin...

Departure of Officer

Investor Conferences

Financial Results Announcement

Annual Meeting Approval

Underwriting Agreement

Phase 2 Dose Announcement

Positive Trial Data Announc...

Financial Results Announcement

Clinical Data Announcement

Preclinical Data Announcement

Regulation FD Disclosure

Sublease Agreement

Financial Results Announcement

Appointment of Chief Operat...

Regulation FD Disclosure

External Links:

Zentalis Pharmaceuticals announced its focus on developing azenosertib for platinum-resistant ovarian cancer, with plans to start a new study and share clinical results showing a 34.8% response rate in a specific patient group.

AI Assistant

ZENTALIS PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.